{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:43:47Z","timestamp":1793108627644,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Switzerland AG"},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Community-acquired pneumonia (CAP) causes significant morbidity and mortality, but Swiss data are limited. We analyzed the Swiss CAPNETZ cohort to describe patient characteristics, pathogens, diagnostics, and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with CAP were prospectively enrolled between 2010 and 2022 at two tertiary hospitals. Data on demographics, comorbidities, microbiology, and outcomes were collected. Mortality was assessed at 28 and 180\u00a0days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 478 patients, 97.7% were hospitalized (median 7\u00a0days), and 76.4% had\u2009\u2265\u20091 comorbidity. ICU admission occurred in 7.3%. Overall mortality was 2.9% at 28\u00a0days and 5.5% at 180\u00a0days, increasing during the COVID-19 pandemic (28-day: 5.7%; 180-day: 10.9%). Higher mortality was observed in older, immunosuppressed, and oncologic patients. The etiological pathogens were detected in 38.3%, and molecular testing of sputum and bronchioalveolar lavage (BAL) enhances pathogen detection rates. Bacterial monoinfections predominated (20.2%), followed by viral (7.4%) and mixed infections (9.5%). Leading pathogens were\n                      <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                      (35.0%) and\n                      <jats:italic>Haemophilus influenzae<\/jats:italic>\n                      (16.1%). In immunocompromised patients,\n                      <jats:italic>H. influenzae<\/jats:italic>\n                      predominated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Overall mortality of CAP stays high.\n                      <jats:italic>S. pneumoniae<\/jats:italic>\n                      remains the most common pathogen overall, while\n                      <jats:italic>H. influenzae<\/jats:italic>\n                      is the most frequent pathogen in immunocompromised patients. Molecular testing of sputum and BAL improves pathogen detection.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-025-02699-2","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:05:23Z","timestamp":1764252323000},"page":"717-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pathogen identification and outcome in adult patients with community-acquired pneumonia in Switzerland: findings from the Swiss CAPNETZ cohort study"],"prefix":"10.1007","volume":"54","author":[{"given":"Samuel","family":"Etienne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner C.","family":"Albrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Panning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Suarez Domenech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grit","family":"Barten-Neiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the CAPNETZ study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"10303","key":"2699_CR1","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0140-6736(21)00630-9","volume":"398","author":"S Aliberti","year":"2021","unstructured":"Aliberti S, et al. Community-acquired pneumonia. Lancet. 2021;398(10303):906\u201319.","journal-title":"Lancet"},{"issue":"7","key":"2699_CR2","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2699_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1055\/s-0029-1202941","volume":"30","author":"T Welte","year":"2009","unstructured":"Welte T, K\u00f6hnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ network. Semin Respir Crit Care Med. 2009;30(2):127\u201335.","journal-title":"Semin Respir Crit Care Med"},{"issue":"6","key":"2699_CR4","doi-asserted-by":"publisher","first-page":"567.e1","DOI":"10.1016\/j.cmi.2016.03.015","volume":"22","author":"AF Simonetti","year":"2016","unstructured":"Simonetti AF, et al. Declining mortality among hospitalized patients with community-acquired pneumonia. Clin Microbiol Infect. 2016;22(6):567.e1-567.e7.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"2699_CR5","doi-asserted-by":"publisher","first-page":"2200735","DOI":"10.1183\/13993003.00735-2022","volume":"61","author":"I Martin-Loeches","year":"2023","unstructured":"Martin-Loeches I, et al. ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J. 2023;61(4):2200735.","journal-title":"Eur Respir J"},{"issue":"1","key":"2699_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191721","volume":"13","author":"M Ferrer","year":"2018","unstructured":"Ferrer M, et al. Severe community-acquired pneumonia: characteristics and prognostic factors in ventilated and non-ventilated patients. PLoS ONE. 2018;13(1):e0191721.","journal-title":"PLoS ONE"},{"issue":"3","key":"2699_CR7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.chest.2020.03.051","volume":"158","author":"R Cavallazzi","year":"2020","unstructured":"Cavallazzi R, et al. The burden of community-acquired pneumonia requiring admission to ICU in the United States. Chest. 2020;158(3):1008\u201316.","journal-title":"Chest"},{"key":"2699_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00286","volume":"6","author":"WC Albrich","year":"2019","unstructured":"Albrich WC, et al. Influence of older age and other risk factors on pneumonia hospitalization in Switzerland in the pneumococcal vaccine era. Front Med. 2019;6:286.","journal-title":"Front Med"},{"issue":"4748","key":"2699_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4414\/smw.2001.09806","volume":"131","author":"L Hug","year":"2001","unstructured":"Hug L, Rossi M. A year\u2019s review of bacterial pneumonia at the central hospital of Lucerne, Switzerland. Swiss Med Wkly. 2001;131(4748):687\u201392.","journal-title":"Swiss Med Wkly"},{"key":"2699_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00096-2018","author":"M Carugati","year":"2018","unstructured":"Carugati M, et al. Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study. ERJ Open Res. 2018. https:\/\/doi.org\/10.1183\/23120541.00096-2018.","journal-title":"ERJ Open Res"},{"key":"2699_CR11","doi-asserted-by":"publisher","first-page":"1258981","DOI":"10.3389\/fpubh.2023.1258981","volume":"11","author":"K Hansen","year":"2023","unstructured":"Hansen K, et al. Exploring the microbial landscape: uncovering the pathogens associated with community-acquired pneumonia in hospitalized patients. Front Publ Health. 2023;11:1258981.","journal-title":"Front Publ Health"},{"key":"2699_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107019","volume":"143","author":"DL Markussen","year":"2024","unstructured":"Markussen DL, et al. Microbial aetiology of community-acquired pneumonia in hospitalised adults: a prospective study utilising comprehensive molecular testing. Int J Infect Dis. 2024;143:107019.","journal-title":"Int J Infect Dis"},{"key":"2699_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107841","volume":"154","author":"F Waldeck","year":"2025","unstructured":"Waldeck F, et al. Comparing viral, bacterial, and coinfections in community-acquired pneumonia, a retrospective cohort study. Int J Infect Dis. 2025;154:107841.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"2699_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s15010-021-01605-w","volume":"49","author":"DCW Braeken","year":"2021","unstructured":"Braeken DCW, et al. Shift in bacterial etiology from the CAPNETZ cohort in patients with community-acquired pneumonia: data over more than a decade. Infection. 2021;49(3):533\u20137.","journal-title":"Infection"},{"issue":"1","key":"2699_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/intqhc\/mzt078","volume":"26","author":"H Uematsu","year":"2014","unstructured":"Uematsu H, et al. Impact of guideline-concordant microbiological testing on outcomes of pneumonia. Int J Qual Health Care. 2014;26(1):100\u20137.","journal-title":"Int J Qual Health Care"},{"issue":"4","key":"2699_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00705-013-1876-3","volume":"159","author":"S Bierbaum","year":"2014","unstructured":"Bierbaum S, et al. Detection of respiratory viruses using a multiplex real-time PCR assay in Germany, 2009\/10. Arch Virol. 2014;159(4):669\u201376.","journal-title":"Arch Virol"},{"issue":"5","key":"2699_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/thorax.58.5.377","volume":"58","author":"WS Lim","year":"2003","unstructured":"Lim WS, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377\u201382.","journal-title":"Thorax"},{"issue":"6","key":"2699_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253118","volume":"16","author":"C Theilacker","year":"2021","unstructured":"Theilacker C, et al. Population-based incidence and mortality of community-acquired pneumonia in Germany. PLoS ONE. 2021;16(6):e0253118.","journal-title":"PLoS ONE"},{"issue":"4","key":"2699_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10096-022-04416-5","volume":"41","author":"V Gl\u00f6ckner","year":"2022","unstructured":"Gl\u00f6ckner V, et al. Early post-discharge mortality in CAP: frequency, risk factors and a prediction tool. Eur J Clin Microbiol Infect Dis. 2022;41(4):621\u201330.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2699_CR20","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2017.14478","volume":"147","author":"A Feller","year":"2017","unstructured":"Feller A, Schmidlin K, Clough-Gorr KM. Trends and socioeconomic inequalities in amenable mortality in Switzerland with international comparisons. Swiss Med Wkly. 2017;147:w14478.","journal-title":"Swiss Med Wkly"},{"key":"2699_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2023.115976","volume":"329","author":"M M\u00fchlichen","year":"2023","unstructured":"M\u00fchlichen M, et al. Different health systems - Different mortality outcomes? Regional disparities in avoidable mortality across German-speaking Europe, 1992-2019. Soc Sci Med. 2023;329:115976.","journal-title":"Soc Sci Med"},{"issue":"2","key":"2699_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041354","volume":"11","author":"K Z\u00fcrcher","year":"2021","unstructured":"Z\u00fcrcher K, et al. Losing ground at the wrong time: trends in self-reported influenza vaccination uptake in Switzerland, Swiss Health Survey 2007\u20132017. BMJ Open. 2021;11(2):e041354.","journal-title":"BMJ Open"},{"key":"2699_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.759602","volume":"9","author":"KD Zens","year":"2021","unstructured":"Zens KD, et al. Pneumococcal vaccination coverage and uptake among adults in Switzerland: a nationwide cross-sectional study of vaccination records. Front Publ Health. 2021;9:759602.","journal-title":"Front Publ Health"},{"key":"2699_CR24","unstructured":"BAG. Bundesamt f\u00fcr Gesundheit, Eidgen\u00f6ssische Kommission f\u00fcr Impffragen. Schweizerischer Impfplan 2025. Richtlinien und Empfehlungen. 2025. Available from: www.bag.admin.ch\/impfplan."},{"issue":"1","key":"2699_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s41479-024-00150-y","volume":"16","author":"C B\u00fcrke","year":"2024","unstructured":"B\u00fcrke C, et al. Effect of the COVID-19 pandemic on hospitalizations for non-COVID-19-pneumonia and exacerbations of chronic obstructive pulmonary diseases in Switzerland: comparison of national data between 2020\/2021 and 2015-2019. Pneumonia. 2024;16(1):24.","journal-title":"Pneumonia"},{"issue":"1","key":"2699_CR26","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41467-022-28157-3","volume":"13","author":"G Konstantinoudis","year":"2022","unstructured":"Konstantinoudis G, et al. Regional excess mortality during the 2020 COVID-19 pandemic in five European countries. Nat Commun. 2022;13(1):482.","journal-title":"Nat Commun"},{"issue":"3","key":"2699_CR27","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s15010-024-02412-9","volume":"53","author":"C Kodde","year":"2025","unstructured":"Kodde C, et al. Comparison of SARS-CoV-2 related in-hospital mortality, ICU admission and mechanical ventilation of 1.4 million patients in Germany and Switzerland, 2019 to 2022. Infection. 2025;53(3):981\u20139.","journal-title":"Infection"},{"key":"2699_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad565","author":"JA Ramirez","year":"2023","unstructured":"Ramirez JA, et al. Community-acquired pneumonia in the immunocompromised host: epidemiology and outcomes. Open Forum Infect Dis. 2023. https:\/\/doi.org\/10.1093\/ofid\/ofad565.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"2699_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1500245","volume":"373","author":"S Jain","year":"2015","unstructured":"Jain S, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415\u201327.","journal-title":"N Engl J Med"},{"issue":"1","key":"2699_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jinf.2013.03.003","volume":"67","author":"DM Musher","year":"2013","unstructured":"Musher DM, et al. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect. 2013;67(1):11\u20138.","journal-title":"J Infect"},{"issue":"9","key":"2699_CR31","doi-asserted-by":"publisher","first-page":"ofaa307","DOI":"10.1093\/ofid\/ofaa307","volume":"7","author":"DM Musher","year":"2020","unstructured":"Musher DM, et al. Normal respiratory flora as a cause of community-acquired pneumonia. Open Forum Infect Dis. 2020;7(9):ofaa307.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2699_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/cid\/ciz876","volume":"71","author":"H Ogawa","year":"2020","unstructured":"Ogawa H, et al. Sputum gram stain for bacterial pathogen diagnosis in community-acquired pneumonia: a systematic review and Bayesian meta-analysis of diagnostic accuracy and yield. Clin Infect Dis. 2020;71(3):499\u2013513.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2699_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s12879-019-4048-6","volume":"19","author":"G Del Rio-Pertuz","year":"2019","unstructured":"Del Rio-Pertuz G, et al. Usefulness of sputum gram stain for etiologic diagnosis in community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis. 2019;19(1):403.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"2699_CR34","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1128\/JCM.02918-14","volume":"53","author":"G Dubourg","year":"2015","unstructured":"Dubourg G, et al. Correlation between sputum and bronchoalveolar lavage fluid cultures. J Clin Microbiol. 2015;53(3):994\u20136.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2699_CR35","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s15010-024-02238-5","volume":"52","author":"A-E Post","year":"2024","unstructured":"Post A-E, et al. The agreement between bronchoalveolar lavage, bronchial wash and sputum culture: a retrospective study. Infection. 2024;52(4):1481\u20138.","journal-title":"Infection"},{"issue":"15","key":"2699_CR36","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jama.2024.14796","volume":"332","author":"VM Vaughn","year":"2024","unstructured":"Vaughn VM, et al. Community-acquired pneumonia: a review. JAMA. 2024;332(15):1282\u201395.","journal-title":"JAMA"},{"issue":"9998","key":"2699_CR37","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0140-6736(15)60733-4","volume":"386","author":"E Prina","year":"2015","unstructured":"Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet. 2015;386(9998):1097\u2013108.","journal-title":"Lancet"},{"issue":"7","key":"2699_CR38","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/cid\/civ1214","volume":"62","author":"NJ Gadsby","year":"2016","unstructured":"Gadsby NJ, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis. 2016;62(7):817\u201323.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2699_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jinf.2022.09.003","volume":"85","author":"S Poole","year":"2022","unstructured":"Poole S, et al. Molecular point-of-care testing for lower respiratory tract pathogens improves safe antibiotic de-escalation in patients with pneumonia in the ICU: results of a randomised controlled trial. J Infect. 2022;85(6):625\u201333.","journal-title":"J Infect"},{"issue":"6","key":"2699_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1473-3099(04)01044-8","volume":"4","author":"S Yang","year":"2004","unstructured":"Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. Lancet Infect Dis. 2004;4(6):337\u201348.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2699_CR41","doi-asserted-by":"publisher","first-page":"e240830","DOI":"10.1001\/jamanetworkopen.2024.0830","volume":"7","author":"DL Markussen","year":"2024","unstructured":"Markussen DL, et al. Diagnostic stewardship in community-acquired pneumonia with syndromic molecular testing: a randomized clinical trial. JAMA Netw Open. 2024;7(3):e240830\u2013e240830.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"2699_CR42","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2213-2600(22)00086-8","volume":"10","author":"AM Darie","year":"2022","unstructured":"Darie AM, et al. Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial. Lancet Respir Med. 2022;10(9):877\u201387.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"2699_CR43","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.cmi.2022.06.021","volume":"28","author":"G Abelenda-Alonso","year":"2022","unstructured":"Abelenda-Alonso G, et al. Effect of positive microbiological testing on antibiotic de-escalation and outcomes in community-acquired pneumonia: a propensity score analysis. Clin Microbiol Infect. 2022;28(12):1602\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"2699_CR44","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.chest.2024.07.144","volume":"167","author":"X Wu","year":"2025","unstructured":"Wu X, et al. Effect of metagenomic next-generation sequencing on clinical outcomes of patients with severe community-acquired pneumonia in the ICU: a multicenter, randomized controlled trial. Chest. 2025;167(2):362\u201373.","journal-title":"Chest"},{"key":"2699_CR45","doi-asserted-by":"publisher","first-page":"1593818","DOI":"10.3389\/fcimb.2025.1593818","volume":"15","author":"N Gao","year":"2025","unstructured":"Gao N, et al. Comparison of bronchoalveolar lavage fluid mNGS and sputum culture in the clinical application of severe pneumonia. Front Cell Infect Microbiol. 2025;15:1593818.","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"2699_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107440","volume":"65","author":"M Yan","year":"2025","unstructured":"Yan M, et al. Metagenomic next-generation sequencing on treatment strategies and prognosis of patients with lower respiratory tract infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2025;65(3):107440.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"2699_CR47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/23744235.2020.1846776","volume":"53","author":"M Fally","year":"2021","unstructured":"Fally M, et al. The increasing importance of Haemophilus influenzae in community-acquired pneumonia: results from a Danish cohort study. Infect Dis. 2021;53(2):122\u201330.","journal-title":"Infect Dis"},{"issue":"1","key":"2699_CR48","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.diagmicrobio.2018.11.014","volume":"94","author":"YK Lim","year":"2019","unstructured":"Lim YK, et al. Impact of bacterial and viral coinfection in community-acquired pneumonia in adults. Diagn Microbiol Infect Dis. 2019;94(1):50\u20134.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2699_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100955","volume":"37","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Outcomes of respiratory viral-bacterial co-infection in adult hospitalized patients. EClinicalMedicine. 2021;37:100955.","journal-title":"EClinicalMedicine"},{"key":"2699_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy010","author":"A Bjarnason","year":"2018","unstructured":"Bjarnason A, et al. Incidence, etiology, and outcomes of community-acquired pneumonia: a population-based study. Open Forum Infect Dis. 2018. https:\/\/doi.org\/10.1093\/ofid\/ofy010.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2699_CR51","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5588\/ijtld.16.0567","volume":"21","author":"DC Braeken","year":"2017","unstructured":"Braeken DC, et al. Bacterial aetiology and mortality in COPD patients with CAP: results from the German competence network, CAPNETZ. Int J Tuberc Lung Dis. 2017;21(2):236\u201343.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"2699_CR52","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","volume":"18","author":"C Troeger","year":"2018","unstructured":"Troeger C, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191\u2013210.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2699_CR53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jinf.2016.01.011","volume":"72","author":"I Grau","year":"2016","unstructured":"Grau I, et al. Declining mortality from adult pneumococcal infections linked to children\u2019s vaccination. J Infect. 2016;72(4):439\u201349.","journal-title":"J Infect"},{"issue":"8","key":"2699_CR54","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/cid\/ciu524","volume":"59","author":"ZB Harboe","year":"2014","unstructured":"Harboe ZB, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066\u201373.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2699_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106502","volume":"59","author":"K Nel Van Zyl","year":"2022","unstructured":"Nel Van Zyl K, et al. Effect of antibiotics on the human microbiome: a systematic review. Int J Antimicrob Agents. 2022;59(2):106502.","journal-title":"Int J Antimicrob Agents"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02699-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02699-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02699-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:02:07Z","timestamp":1774555327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02699-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2699"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02699-2","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Werner C. Albrich: Honoraria: Pfizer, GSK, MSD, A.Vogel; travel support: Pfizer, Gilead, GSK; advisory boards: Pfizer, MSD, GSK, Sanofi, Moderna, Janssen, Aurovir Grit Barten: public funding for the CAPNETZ study conduct from Deutsches Zentrum f\u00fcr Lungenforschung (DZL) and from Pfizer Deutschland GmbH. Daiana Stolz: Honoraria: AstraZeneca, Berline-Chemie Menarini, Boehringer Ingelheim, Chiesi, CSL Behring, Insmed, GSK. Pfizer, MSD, Novartis, Sanofi, Vifor, Roche, OM-Pharma, Roche. Leadership: Current GOLD representative for Switzerland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}